We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Thalomid Strategy Tests Goal to Avoid REMS as a Barrier to Generics
Thalomid Strategy Tests Goal to Avoid REMS as a Barrier to Generics
October 5, 2010
Thalomid, more commonly known as thalidomide, created a situation that tested the Food and Drug Administration Amendments Act’s (FDAAA’s) attempt to keep risk evaluation and mitigation strategies (REMS) from being a market barrier to generics.